Phase 3 Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a head and neck cancer (confirmed by a lab test on a tissue or cell sample) and your treatment plan includes a chemotherapy drug called cisplatin, given either weekly (7 doses) or every 3 weeks (3 doses), adding up to a total dose of at least 200mg/m²
- Your planned cisplatin treatment will be no more than 7 cycles in total
- You are willing and able to sign a consent form agreeing to take part
- You are generally well enough to carry out some or all of your normal daily activities (this is measured on a standard medical scale — confirm with trial site)
- You are over 18 years old
Who may not be able to join:
- You already have a significant difference in hearing between your two ears before treatment starts (confirm with trial site for exact details)
- You already have a notable level of hearing loss in one or both ears before treatment begins (confirm with trial site for exact details)
- Your treatment plan includes a high dose of radiation directed at a specific part of the inner ear (the cochlea)
- You have a known allergy or sensitivity to the gel-based study treatment used in this trial
- You have any other condition that the trial doctor believes would make it unsafe or impractical for you to take part
- You have a condition affecting your ear canal or middle ear that could prevent the study gel from reaching the right part of the inner ear — for example, a narrowed ear canal, a specific type of bone condition in the ear, or fluid behind the eardrum (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lotje Zuur, Prof. Dr., AVL
Phone: +31205129111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The efficacy (clinically relevant benefit) of transtympanic STS 0.1M/0.5 HYA against platinum-related ototoxicity.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.